The 2026 RAS Drug Development Landscape Report
The RAS therapeutic landscape is evolving across both early and late-stage development pipelines.
This Report Offers Insight Into:
- Preclinical Pipeline Trends: Track activity by disease indication, top targets, and emerging modalities shaping early-stage RAS innovation.
- Emerging Preclinical Assets: The high-potential preclinical programmes to watch in 2026.
- Clinical Stage Development: Clinical trial trends and how leading developers are positioning in an increasingly competitive space.
- Deal and Partnership Activity: The licensing agreements and collaborations driving momentum across the RAS landscape.
You May Also Be Interested In…
Learn More About Oncology
What is Beacon Oncology?
- The Most Comprehensive Way to Search the Oncology Drug Development Landscape: Unique search ontologies based on Oncology drug and trial characteristics
- Market Leading Approach to Oncology Preclinical & Clinical Data Curation: Manual curation of key Oncology research and development data points by Oncology research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Oncology company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
